Provided herein are compounds of the Formula I:and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2and Ryhave the meanings given in the specification, which are inhib...
标准号:
TW201938563(A)
Provided herein are compounds of the Formula I:and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2and Ryhave the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Provided herein are compounds of the Formula I:and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2and R3have the meanings given in the specification, which are inhibitors of RET ki...
标准号:
TW201932464(A)
Provided herein are compounds of the Formula I:and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2and R3have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
暂无评论